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EvOBJECTIVES The aim of BIOLUX P-II (BIOTRONIK’S–First in Man study of the Passeo-18 LUX drug releasing PTA Balloon
Catheter vs. the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal ar-
teries) trial was to compare the safety and efﬁcacy of a novel paclitaxel-coated drug-eluting balloon (DEB) versus an
uncoated balloon (percutaneous transluminal angioplasty [PTA]) in de novo or native restenotic lesions of the infrapo-
pliteal arteries in patients with claudication and critical limb ischemia.
BACKGROUND DEB have shown promising results in femoropopliteal lesions, but data for infrapopliteal lesions
are scarce.
METHODS In this prospective, multicenter, randomized ﬁrst-in-man study, 72 patients were randomized 1:1 to either a
Passeo-18 Lux DEB (Biotronik AG, Buelach, Switzerland) (n¼ 36) or Passeo-18 PTA (n¼ 36). Follow-up assessments were
scheduled at 1, 6, and 12 months, with angiographic assessment at 6 months. Adverse events were adjudicated by an in-
dependent clinical events committee, and angiographic parameters were assessed by an independent core laboratory.
RESULTS The primary safety endpoint (a composite of all-cause mortality, target extremity major amputation, target
lesion thrombosis, and target vessel revascularization at 30 days) was 0% in the DEB group versus 8.3% in the PTA group
(p ¼ 0.239). The primary performance endpoint (patency loss at 6 months) was 17.1% in the DEB group versus 26.1% in
the PTA group (p ¼ 0.298), and major amputations of the target extremity occurred in 3.3% versus 5.6% of the patients
at 12 months, respectively.
CONCLUSIONS The Passeo-18 Lux DEB has been proven to be safe and effective in infrapopliteal lesions with com-
parable outcomes to PTA. (J Am Coll Cardiol Intv 2015;8:1614–22) © 2015 by the American College of Cardiology
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1615AB BR E V I A T I O N S
AND ACRONYM S
ABI = ankle brachial index
BTHC = n-Butyryl tri-n-hexyl
citrate
CLI = critical limb ischemia
DEB = drug-eluting balloon
MAE = major adverse event(s)
OPG = objective performance
goal
PTA = percutaneous
transluminal angioplasty
QVA = quantitative vascular
angiography
TLR = target lesion
cularizationP eripheral artery disease of the lower extrem-ities is the third leading cause of atheroscle-rotic cardiovascular morbidity and is
increasing dramatically as the population ages (1,2).
Infrapopliteal atherosclerosis is the most common
cause of critical limb ischemia (CLI), which is asso-
ciated with poor prognosis regarding limb preserva-
tion and survival in patients with tissue involvement
(3). Patients with CLI have an increased risk for compli-
cations after open surgical revascularization, and
therefore, an endovascular-ﬁrst strategy is recommen-
ded in infrapopliteal lesions with stent placement be-
ing reserved as bail out option (3,4). Drug-eluting
balloons (DEBs) appear to be a good alternative to
percutaneous transluminal angioplasty (PTA) with un-
coated balloons as they combine the advantage of drug
delivery without the disadvantages of a permanent
stent. Hence, they are thought to reduce restenosis
rates, one of the major limitations of PTA. DEBs have
been proven to be superior to PTA in several random-
ized trials in femoropopliteal lesions (5–8), but data
in infrapopliteal lesions are scarce.SEE PAGE 1623The Passeo-18 Lux DEB (Biotronik AG, Buelach,
Switzerland) is coated with paclitaxel, which is in-
corporated in a deliverymatrix of n-Butyryl tri-n-hexyl
citrate (BTHC). Promising results have been obtained
using the same formulation in animal studies and
coronary lesions (9,10) and using the Passeo-18 Lux in
femoropopliteal lesions (8). The purpose of the BIO-
LUX P-II (BIOTRONIK’S–First in Man study of the Pas-
seo-18 LUX drug releasing PTA Balloon Catheter vs. the
uncoated Passeo-18 PTA balloon catheter in subjects
requiring revascularization of infrapopliteal arteries)
ﬁrst-in-man trial was to prospectively evaluate the
safety and performance of this novel DEB versus PTA
for the treatment of stenotic, restenotic, or occluded
infrapopliteal arteries excluding in-stent restenosis in
patients experiencing claudication or CLI.received consulting fees from Medtronic, Gore, Cook, Bard Peripheral Vascu
on the advisory board of Medtronic, Boston Scientiﬁc, and Gore; and is a
Angioslide, Veryan, Cordis Corp., Spectranetics, Straub Medical, TriReme,
personal fees from Biotronik outside of the submitted work. Prof. Dr. Sch
board of Abbott, Angioslide, Atheromed, Biotronik, Boston Scientiﬁc, Cook
Hemoteq, Intact Vascular Inc., Medtronic, Ostial Inc., TriReme Medical, Triva
Dr. Schulte is a member of the advisory boards of Bayer, Eurocor, Merck Sh
fees/honoraria from Bard, Biotronik, Boston Scientiﬁc, Covidien, and Euro
AstraZeneca, Bard, Biotronik, Boston Scientiﬁc, Eurocor, Covidien, IDEV, Lut
fees/honoraria from Terumo, Medtronic, Covidien, Abbott, Volcano, and Ba
from Medtronic, Bard, Covidien, and Biotronik. All other authors have repo
contents of this paper to disclose.
Manuscript received April 15, 2015; revised manuscript received June 23, 20METHODS
STUDY DESIGN AND POPULATION. BIOLUX P-II
is a prospective, international, multicenter,
randomized, controlled, ﬁrst-in-man study,
aiming to assess the safety and performance
of the Passeo-18 Lux paclitaxel-coated
DEB versus the uncoated Passeo-18 balloon
catheter (PTA) in patients with stenosis,
restenosis, or occlusion of the infrapopliteal
arteries (excluding in-stent restenosis and
experiencing claudication or CLI).
The study is registered at ClinicalTrials.gov
(NCT01867736), where the full set of inclusion
and exclusion criteria is available. The main
inclusion criteria were single or sequential de
novo or restenotic lesions excluding in-stent reste-
nosis ($70% diameter reduction or occlusion) in the
infrapopliteal arteries $30 mm, a maximum of 2
different vessels to be treated, reference vessel diam-
eter of 2 to 4 mm based on visual estimation, in-ﬂow
free from ﬂow-limiting lesion, at least 1 nonoccluded
crural vessel with angiographically documented run-
off to the foot, and successful wire crossing of the
lesion. Main exclusion criteria were lesions extending
beyond the ankle joint, acute thrombus in the target
vessel, planned major amputation of the target limb,
previous bypass surgery of the target vessel, or previ-
ous stent implantation in the target lesion. Randomi-
zation was performed after successful wire passage
through the lesion via the electronic case report form.
Patients were allocated to DEB and PTA in a 1:1 ratio,
with block sizes of 4 and 6.
Prior to DEB treatment, lesion preparation was
recommended to be performed with an uncoated
balloon that was shorter and smaller than the DEB.
Thereby, pre-dilation should follow current hos-
pital practice. Pre-dilation for PTA lesions was not
required. In case of insufﬁcient treatment results,
post-dilation with a Passeo-18 uncoated balloon was
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1616allowed, and in case of ﬂow-limiting dissection, a
bare-metal stent could be placed. Control arm an-
gioplasty, as well as provisional stenting, should
follow the manufacturer’s current instructions for
use. Dual antiplatelet therapy was recommended for
1 month post-procedure (acetylsalicylic acid 100 to
325 mg/day and clopidogrel 75 mg/day) and for 3
months in case of bailout stenting with a bare-metal
stent. Clinical follow-up was scheduled at 30 days,
6 months, and 12 months, and angiographic follow-up
at 6 months.
The study was conducted according to the Declara-
tion of Helsinki, International Conference on Harmo-
nisation of Technical Requirements for Registration of
Pharmaceuticals for Human Use–Good Clinical Prac-
tice, and International Organization for Standardiza-
tion’s ISO 14155:2011, and approved by the respective
independent ethical committees. All patients pro-
vided written informed consent prior to any study
procedure. Monitoring included 100% source docu-
ment veriﬁcation. Quantitative vascular angiographyFlow Diagram
e was 91.7% for the DEB versus 100.0% for the uncoated balloon
llow-up and 80.6% versus 94.4%, respectively, at 12-month follow-
ing balloon; FUP ¼ follow-up; PTA ¼ percutaneous transluminal(QVA) analysis was performed by an independent core
laboratory (CoreLab Bad Krozingen GmbH, Bad Kro-
zingen, Germany) that was blinded to the treatment,
and all adverse events were adjudicated by an inde-
pendent clinical events committee.
STUDY DEVICES. The Passeo-18 Lux paclitaxel-
coated balloon is identical to the Passeo-18 balloon
catheter (Biotronik AG), but additionally is homoge-
neously coated with 3 mg paclitaxel per mm2 balloon
surface as a lipophilic antiproliferative substance.
Paclitaxel is incorporated in a delivery matrix of
BTHC as excipient, which incorporates paclitaxel
into a microcrystalline structure to improve drug
uptake into the vessel wall (9) and which degrades
to citric acid and alcohol. Passeo-18 Lux is manufac-
tured using a proprietary pipetting process designed
to ensure homogenous coating distribution, 100%
dosage control, and reproducible chemical and me-
chanical properties of the device. The unique combi-
nation of drug, excipient, balloon surface properties,
and coating process is designed for the right balance
between coating adhesion and drug release. Bare
balloons are coated in an uninﬂated state, and ho-
mogeneity is controlled by making use of capillary
effects. For the purpose of this study, the range of
available sizes, which included sizes 3 to 7 mm, had
been extended to include the small sizes 2.0 and 2.5
mm. Balloon lengths ranged from 40 to 120 mm.
ENDPOINTS AND DEFINITIONS. The primary safety
endpoint was 30-day major adverse event (MAE) rate,
deﬁned as a composite of all-cause mortality, major
amputation of the target extremity, target lesion
thrombosis, and target vessel revascularization. The
primary performance endpoint was 6-month target
lesion primary patency, deﬁned as <50% restenosis in
the target lesion assessed by QVAwithout target lesion
revascularization (TLR). Secondary endpoints were:
1) device success, deﬁned as exact deployment ac-
cording to instructions for use; 2) technical success,
deﬁned as successful vascular access, completion of
procedure, and residual stenosis <30%; 3) procedural
success, deﬁned as device or technical success without
the occurrence of MAEs during the hospital stay;
4) binary restenosis and 5) late lumen loss at 6 months
assessed by QVA; 6) TLR; 7) target vessel revasculari-
zation and 8) MAE at 6 and 12 months; 9) change in
ankle brachial index (ABI) and 10) Rutherford classi-
ﬁcation at 30 days, 6 months, and 12 months; and
11) quality of life at 6 and 12months. Vessel calciﬁcation
was assessed using the COMPLIANCE 360 score (11).
STATISTICAL ANALYSIS. On the basis of the as-
sumption of a 65% binary restenosis rate in the PTA
group and a 45% relative risk reduction in the DEB
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1617group, it was calculated that a sample size of 46 le-
sions per group would yield a power of 80% consid-
ering a 2-sided test with a 5% signiﬁcance level.
Considering a 15% drop out rate and 1.5 lesions per
subject, this corresponds to a ﬁnal number of 36 pa-
tients/group. The endpoint analysis was performed
on the basis of available data on the intention to treat
population (i.e., subjects are analyzed in the groups
to which they were randomized to and no subjects
were excluded from analysis).
Continuous variables were summarized with mean
 SD. Categorical variables were summarized with
frequencies and percentages. The following tests were
applied when appropriate for group comparison:
Student t, Mann-Whitney U, Fisher exact, chi-square,
McNemar’s, and log-rank tests. Survival analysis was
carried out using the Kaplan-Meier estimator. The
SAS statistical software (version 9.3, SAS Institute,
Cary, North Carolina) was used for all statistical
calculations.
RESULTS
BASELINE CHARACTERISTICS. Between July 2012
and June 2013, 72 patients were randomized in 6 cen-
ters in Europe to either Passeo-18 Lux DEB (n ¼ 36, 50
lesions) or PTA (n ¼ 36, 55 lesions) (Figure 1).TABLE 1 Baseline Characteristics
DEB
(n ¼ 36)
PTA
(n ¼ 36) p Value
Male 27 (75.0) 30 (83.3) 0.384
Age, yrs 72.9  10.3,
4591
69.6  8.9,
5392
0.153
BMI, kg/m2 27.9  4.1,
2239
27.4  4.7,
1843
0.736
Hypertension 31 (86.1) 31 (86.1) >0.999
Hyperlipidemia 26 (72.2) 23 (63.9) 0.448
Smoking 20 (55.6) 20 (55.6) >0.999
Current smoker 4 (20.0) 6 (30.0) 0.716
Diabetes 22 (61.1) 26 (72.2) 0.317
Insulin-dependent 14 (63.6) 17 (65.4) 0.900
History of previous PAD 17 (47.2) 22 (61.1) 0.237
Coronary artery disease 15 (41.7) 15 (41.7) >0.999
Cerebrovascular disease 13 (36.1) 9 (25.0) 0.306
Renal insufﬁciency 10 (27.8) 10 (27.8) >0.999
Cancer 3 (8.3) 3 (8.3) >0.999
Rutherford class 4.5  0.9,
25
4.4  1.0,
25
0.915
2: moderate claudication 1 (2.8) 3 (8.3)
0.915
3: severe claudication 7 (19.4) 5 (13.9)
4: ischemic rest pain 2 (5.6) 2 (5.6)
5: minor tissue loss 26 (72.2) 26 (72.2)
Values are n (%), mean  SD, or minimum to maximum. Entries in italics represent
subcohorts of the entire cohort of smokers and diabetic patients.
BMI ¼ body mass index; DEB ¼ drug-eluting balloon; PAD ¼ peripheral artery
disease; PTA ¼ percutaneous transluminal angioplasty.There was no signiﬁcant difference in terms of
baseline characteristics (Table 1). Mean age was 72.9 
10.3 years for DEB patients and 69.6  8.9 years for
PTA patients, and diabetes was present in 61.1% and
72.2%, respectively. Approximately three-fourths of
patients had Rutherford class 5 (minor tissue loss),
and one-half of the patients had a smoking history or
a history of previous peripheral artery disease and
concomitant coronary artery disease. Lesion and
procedure details are depicted in Table 2. The DEB
group had signiﬁcantly less lesions without calciﬁca-
tion than the PTA group (55.9% vs. 81.6%; p ¼ 0.018),
and more lesions with moderate to severe calciﬁca-
tions (26.5% vs. 7.9%; p ¼ 0.056), all other parameters
were not signiﬁcantly different amongst the groups.
Mean treated lesion lengths were 113.1  88.1 mm and
115.0  86.9 mm, respectively.
PROCEDURAL CHARACTERISTICS. Inﬂow lesions
were treated in 50% of the patients in the DEB and
30.6% of the patients in the PTA group (p ¼ 0.093).
Overall, 139 balloons were used to treat 105 target
lesions. Mean device diameter was 2.5 mm (range 2.0
to 4.0 mm) (Table 3). No bailout stenting was
required. Minimum lumen diameter increased from
0.63  0.63 mm and 0.62  0.53 mm at baseline to 1.59
 0.46 mm and 1.59  0.65 mm, respectively, post-
procedure (Table 2).
ENDPOINTS. The primary safety endpoint, MAE at
30 days, occurred in none (0.0%) of the patients in the
DEB group versus in 8.3% of the PTA group. At
12 months, 41.1% (DEB) versus 39.1% (PTA) of the
patients experienced an MAE event, and 3.3% versus
5.6% experienced a major amputation of the target
extremity (Table 4). All patients experiencing a major
amputation were in Rutherford class 5 (minor tissue
loss) at baseline, had diabetes, and presented with a
reference vessel diameter of #2.5 mm. One target
lesion thrombosis occurred in the PTA group.
The primary performance endpoint, lesion-based
patency loss at 180 days by QVA, was observed in
17.1% of DEB lesions and 26.1% of PTA lesions;
subject-based primary patency loss was 20.3% and
26.6%, respectively. At 6 months, the Kaplan-Meier
curves for patency loss and TLR (clinically- and not
clinically-driven) increased sharply (Figure 2);
notably, 80% of the TLR in the DEB group occurred
during 6-month angiography. At 12 months, patency
loss occurred in 20 lesions (50.8%) in the DEB and 22
lesions (45.6%) in the PTA group. Overall, lesions
requiring a TLR were totally occluded at baseline in
70% (DEB) and 50% (PTA) of the cases, with lesion
length ranging between 80 to 302 mm (DEB) and 40 to
279 mm (PTA). Late lumen loss at 6 months was 0.56
TABLE 2 Lesion Characteristics at Baseline and Follow-Up Per
Core Laboratory Assessment
Baseline*
DEB PTA p Value
n 50 54
Lesion location
0.693
Anterior tibial artery 24 (48.0) 25 (46.3)
Posterior tibial artery 11 (22.0) 12 (22.2)
Peroneal artery 7 (14.0) 11 (20.4)
Tibioperoneal trunk 5 (10.0) 2 (3.7)
Other 3 (6.0) 4 (7.4)
Calciﬁcation† —
None 19 (55.9) 31 (81.6) 0.018
Mild 6 (17.6) 4 (10.5) 0.501
Moderate 1 (2.9) 0 (0.0) 0.472
Moderate/severe 3 (8.8) 1 (2.6) 0.338
Severe 5 (4.7) 2 (5.3) 0.243
Moderate to severe 9 (26.5) 3 (7.9) 0.056
Thrombus present 0 (0.0) 0 (0.0) >0.999
Treated lesion length, mm 113.1  88.1,
24351
115.0  86.9,
39295
0.960
MLD, mm 0.63  0.63,
0.01.78
0.62  0.53,
0.01.64
0.986
RVD, mm 2.28  0.54,
1.404.02
2.19  0.57,
1.213.93
0.246
Stenosis pre-procedure 72.5  25.4,
31100
72.1 23.2,
30100
0.936
Number of crural vessels with run-off the foot 1.7  0.8,
03
1.7  0.9,
03
0.565
Lesions per subject (n ¼ 72)
0.375
1 24 (66.7) 20 (55.6)
2 10 (27.8) 14 (38.9)
3 2 (5.6) 2 (5.6)
Post-Procedure
n 48 52
MLD, mm 1.59  0.46,
0.812.88
1.59  0.65,
0.03.94
0.888
Stenosis, % 29.7  11.0,
13.555.0
30.5  16.5,
2.0100.0
0.796
6 Months
n 32 30
Binary restenosis
At 6-month interval 17 (53.1) 12 (41.4) 0.359
At 180 days‡ 6 (14.6) 10 (20.1) 0.480
MLD, mm 1.04  0.81,
0.02.43
1.02  0.76,
0.02.48
0.921
Stenosis, % 56.9  30.7,
13.8100.0
51.1  31.3,
10.7100.0
0.454
Late lumen loss, mm 0.56  0.65
(0.3–0.8),
0.481.79
0.54  0.66
(0.3–0.8),
0.431.93
0.913
Values are n (%); mean  SD, minimum to maximum; or mean  SD (95% conﬁdence interval), minimum to
maximum. *1 lesion of the uncoated balloon group without data. †16 lesions in each group without information;
mild: calcium deposits <180 (on 1 side of vessel) in circumference and <50% of total lesion length; moderate:
calcium <180 in circumference and $50% of length; moderate/severe: calcium $180 in circumference
and <50% of length; severe: calcium$180 in circumference and$50% of lesion length (11). ‡Per Kaplan-Meier
estimate.
MLD ¼ minimal lumen diameter; NA ¼ not available; RVD ¼ reference vessel diameter; other abbreviations as
in Table 1.
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1618 0.65 mm for DEB lesions versus 0.54  0.66 mm for
PTA lesions (p ¼ 0.913) (Table 4). Notably, the core
laboratory assessed 2 PTA lesions as 1, so that the
number of lesions per core laboratory is 54.
Comparing CLI with non-CLI patients, MAE esti-
mates at 12 months were 46.9% (n ¼ 11) versus 25.0%
(n ¼ 2) for the DEB group (p ¼ 0.362) and 39.7% (n ¼
11) versus 37.5% (n ¼ 3) for the PTA group (p ¼ 0.913).
Lesion-based TLR estimates were 34.6% (n ¼ 11)
versus 12.5% (n ¼ 1) (p ¼ 0.257) and 31.6% (n ¼ 11)
versus 28.6% (n ¼ 4) (p ¼ 0.881), respectively.
Excluding patients with major amputation, mean
Rutherford class improved from 4.50.9 at baseline to
2.3  2.3 at 6 months in the DEB group and from 4.4 
1.0 to 2.7  2.4 in the PTA group (Figure 3). Including
patients with major amputation and counting them as
Rutherford class 6, Rutherford class at 6 months was
2.4  2.3 in the DEB group and 2.9  2.4 in the PTA
group. No patient in the DEB group had a worsening of
Rutherford class versus 6.3% in the PTA group.
Clinical outcomes at 30 days; Rutherford classiﬁ-
cation at 1, 6, and 12 months; quality of life (EQ-5D
[EuroQol 5 Dimensions]) questionnaire; and ABI
measurements are provided in the Online Appendix
(Online Tables S1 to S4). Notably, one-half of the pa-
tients in both groups returned to a normal ABI at 1
month. This result was sustained at 12 months.
DISCUSSION
In the BIOLUX P-II trial, clinical and performance
outcomes did not differ signiﬁcantly between pa-
tients treated with DEB and patients treated with
PTA. Therefore, the primary study hypothesis, a
45% relative risk reduction for binary restenosis, was
not met. As in the IN.PACT-DEEP (Study of IN.PACT
Amphirion Drug Eluting Balloon vs. Standard PTA
for the Treatment of Below the Knee Critical Limb
Ischemia) (12): 1) no biological efﬁcacy of the drug
coating could be observed; and 2) the safety and per-
formance outcomes for the PTA group were surpris-
ingly good. In contrast to IN.PACT-DEEP, there was no
safety signal in the BIOLUX P-II trial, and the DEB
group had numerically less major amputations of the
target extremity (n ¼ 1, 3.3% vs. n ¼ 2, 5.6% for the
overall study population, and 4.3% vs. 7.1% in CLI
patients; p ¼ NS); no additional major amputation
occurred beyond 6 months. Yet, when interpreting the
results, it has to be considered that the trial was not
powered to detect differences in clinical outcomes.
Overall, the results obtained in BIOLUX P-II were
good in both groups. For CLI patients treated in
German hospitals, Malyar et al. (2) reported in-
hospital mortality and major amputation rates of
TABLE 3 Procedural Characteristics
DEB PTA p Value
Inﬂow lesions treated 18 (50.0) 11 (30.6) 0.093
Pre-dilation performed 42 (87.5) 15 (32.5) <0.001
Pre-dilation balloon diameter, mm 1.9  0.3 2.1  0.4 0.027
Maximum pressure applied, atm 8.7  2.0 8.4  1.8 0.683
Cumulative inﬂation time pre-dilation, s 50.1  28.3 33.4  14.9 0.010
Device diameter, mm 2.5  0.4 2.5  0.5 0.851
Pressure applied at ﬁrst inﬂation, atm 8.4  3.3 7.9  2.0 0.861
Inﬂation time ﬁrst inﬂation, s 89.9  44.8 71.7  40.2 0.007
Device success (device based) 68 (91.9) 61 (93.8) 0.750
Technical success (lesion based)
<30% residual stenosis 26 (54.2) 31 (59.6) 0.687
<50% residual stenosis 43 (89.6) 47 (90.4) >0.999
Procedural success (patient based) 34 (94.4) 30 (83.3) 0.260
Values are n (%) or mean  SD
Abbreviations as in Table 1.
TABLE 4 Time-To-Event Estimates of Clinical Outcomes at
Follow-Up
DEB PTA p Value
180 Days
MAE 8 (24.8) 9 (25.0) 0.944
Death 2 (6.1) 1 (2.9) 0.499
In CLI patients only 1 (4.0) 1 (3.7) 0.921
Amputation target extremity 8 (23.7) 7 (19.6) 0.619
Major 1 (3.3) 2 (5.6) 0.631
TLR lesion 6 (14.6) 10 (19.7) 0.460
Subject based 5 (16.8) 6 (17.5) 0.881
TVR 5 (16.8) 6 (17.5) 0.881
Target lesion thrombosis 0 (0.0) 1 (2.8) >0.999
Patency loss (lesion based)* 7 (17.1) 13 (26.1) 0.298
365 Days
MAE 13 (41.1) 14 (39.1) 0.957
Death 3 (9.4) 2 (6.0) 0.575
In CLI patients only 2 (8.6) 2 (7.9) 0.917
Amputation target extremity 8 (23.7) 9 (25.7) 0.988
Major 1 (3.3) 2 (5.6) 0.631
In CLI patients only 1 (4.3) 2 (7.1) 0.636
TLR
Lesion based 12 (30.1) 15 (30.6) 0.805
Subject based 10 (34.9) 10 (30.0) 0.817
Clinically driven TLR,
subject based
9 (31.3) 9 (26.9) 0.805
TVR 10 (34.9) 10 (30.0) 0.817
Target lesion thrombosis 0 (0.0) 1 (2.8) >0.999
Patency loss (lesion based)* 20 (50.8) 22 (45.6) 0.908
Values are n (%). *Per core laboratory analysis.
CLI ¼ critical limb ischemia; MAE ¼ major adverse events (composite of all-
cause death, major amputation of target extremity, target lesion thrombosis,
and target vessel revascularization); TLR ¼ target lesion revascularization; TV ¼
target vessel; TVR ¼ target vessel revascularization; other abbreviations as in
Table 1.
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16198.4% and 3.5% for CLI patients. In BIOLUX P-II DEB
patients with CLI at baseline, results were far better,
with a 30-day mortality and major amputation rate of
0%. Furthermore, Conte et al. (13) suggested objective
performance goals (OPGs) for treatment of patients
with CLI and infrapopliteal lesions such as the
following: 30-day safety OPGs for major amputation
4%, 1-year OPGs for limb salvage, and survival of 82%
and 80%. In our series, both treatment arms were far
below those values.
Compared with other trials with DEBs in infrapo-
pliteal lesions, BIOLUX P-II had the smallest vessel
diameter (2.3 mm vs. 2.5 to 2.9 mm [12,14,15]), which
might have inﬂuenced revascularization rates. Late
lumen loss was 0.56 mm for the DEB group and
0.54 mm for the PTA group in the BIOLUX P-II trial
at 6 months compared with 0.61 and 0.62 mm at
12 months in IN.PACT-DEEP (12). Major amputation at
12 months was 3.3% for the overall DEB cohort and
4.3% in DEB-CLI patients compared with 0% (14),
4.4% (15), and 8.8% (12) reported in the published
data. Despite the comparable angiographic parame-
ters, 12-month TLR rate in the BIOLUX P-II trial was
considerably higher than in other series (30.1% for
DEB and 30.6% for PTA compared with 11.9% and
13.9% in IN.PACT-DEEP [12], 18% and 29% in
DEBATE-BTK (Drug-eluting balloon in peripheral
intervention for below the knee angioplasty evalua-
tion) [14], and 17.3% in a single-center non-
randomized series [15]). This difference might be best
explained by the fact that the BIOLUX P-II trial did
mandate a 6-month angiography, whereas for
IN.PACT-DEEP (12) and DEBATE-BTK (14), the angio-
graphic assessment was performed at 12 months. It is
very likely that investigators treated even clinically
asymptomatic restenosis or occlusions during the 6-
month angiography. That assumption is underlined
by the fact that 80% of the TLR in the DEB group were
done at the 6-month angiography, and the TLR curve
increases sharply around 6 months.
The ability to compare the results of BIOLUX P-II to
those of DES in infrapopliteal lesions is hampered, as
most of the DES trials have been conducted in short
lesions. Baumann et al. (16) have summarized the
most relevant studies conducted with DES (Achilles,
Destiny [Drug Eluting Stents In The Critically
Ischemic Lower Leg], Below, Yukon BTK Trial, and a
study by Falkowski et al.). In these studies, primary
patency ranged from 84.0% to 91.0% at 6 months and
from 77.6% to 85.0% at 12 months; however, the
maximum average lesion length was only 31 mm. One
small, single-center study in 50 patients compared a
paclitaxel-eluting stent with a paclitaxel-eluting
balloon in long infrapopliteal lesions ($70-mm
FIGURE 2 Course of Target Lesion Revascularization and Patency Loss Per Kaplan-Meier Estimates
(A) Target lesion revascularization; (B) patency loss. Data are lesion based. Abbreviations as in Figure 1.
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1620lesion length). With a mean lesion length of 127 mm in
the DES group and 148 mm in the DEB group, 6-
month binary restenosis was 28% in the DES group
versus 58% in the DEB group (p ¼ 0.046) and TLR was
7.7% versus 13.6% (p ¼ 0.65), respectively (17).
What are potential reasons for the negative study
outcome?FIGURE 3 Box Plots of Rutherford Classiﬁcation at 6 Months Comp
The ends of the boxes represent the ﬁrst and third quartiles, the vertic
whiskers the minimum and maximum. Open circles = the lowest Ruther1. In the BIOLUX P-II trial, PTA lesions were signiﬁ-
cantly less calciﬁed at baseline compared with DEB
lesions—a known predictor for reduced DEB efﬁ-
cacy in PAD (18).
2. Difference in pre-dilation requirements and dila-
tion time might have biased outcomes, as this
might have caused additional trauma. Eventually,ared With Baseline
al line the median, the solid diamond the mean, and the end of the
ford category at baseline. Abbreviations as in Figure 1.
PERSPECTIVES
WHAT IS KNOWN? DEBs have proven to be superior to un-
coated balloons in femoropopliteal lesions, but recent data for
infrapopliteal lesions obtained from the IN.PACT-DEEP trial were
discouraging.
WHAT IS NEW? We compared a novel DEB with a BTHC
excipient (Passeo-18 Lux) to an uncoated balloon (Passeo-18) in
a small series of patients with infrapopliteal lesions. Although
the overall results were good and Passeo-18 Lux DEB proved to
be safe, outcomes were not superior to uncoated balloons as
seen in femoropopliteal lesions.
WHAT IS NEXT? Future studies are needed to better understand
the mechanism of DEB treatment in infrapopliteal lesions and to
identify patient and lesion groups that may beneﬁt from this
treatment option.
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1621the techniques of angioplasty in infrapopliteal le-
sions need to be re-evaluated in respect to balloon
sizing, inﬂation time, repetitive inﬂations, and
inﬂation and deﬂation times.
3. Kashyap et al. (19) showed that angiography un-
derestimates the degree of stenosis and calciﬁca-
tion and overestimates the luminal diameter in
tibial arteries compared with histological assess-
ment. This may lead to a suboptimal sizing of
interventional devices such as balloon angioplasty
catheters. Adjunctive imaging assessment, such as
intravascular ultrasound, may be useful for
ensuring an optimized device sizing and hence
improving durability of the intervention.
4. A potential explanation for different outcomes
of DEB angioplasty in femoropopliteal lesions
comparedwith infrapopliteal lesionsmight be drug-
loss during advancement to the lesion with small
diameter, as discussed for In.Pact Amphirion
(Medtronic, Fridley, Minnesota) (20,21).
There are still a variety of unanswered questions.
Studies are needed to better understand the drug
delivery in infrapopliteal lesions, to better under-
stand the effect of angioplasty in this vessel area,
to assess to which extent additional imaging mo-
dalities might improve clinical outcomes, and to
assess which treatment is best suited for a speciﬁc
patient population.
STUDY LIMITATIONS. The BIOLUX P-II trial included
only a small number of patients presenting with
claudication and CLI. Furthermore, no wound heal-
ing was assessed. The mandated angiography at 6
months led to an artiﬁcial increase in TLR and made
it difﬁcult to distinguish between true clinically
driven revascularizations and revascularizations that
were done based on angiographic parameters. To
avoid such bias, future studies should include a
clinical follow-up at 12 months and the angiographic
follow-up thereafter.CONCLUSIONS
In a small patient population including claudicants
and CLI patients, DEB treatment has proven to be
safe, with comparable outcomes to PTA. Future
studies are needed to better understand the under-
lying mechanisms in this complex lesion setting and
to deﬁne patient groups that might beneﬁt from DEB
treatment.
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